Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 6/20 | 0.69 |
| ▸ | MMP1 | P03956 | 5/20 | 0.69 |
| ▸ | MMP2 | P08253 | 5/20 | 0.69 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.56 |
| ▸ | FCER2 | P06734 | 4/20 | 0.55 |
| ▸ | MMP7 | P09237 | 3/20 | 0.53 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808350 | 0.89 | MMP1 (0.54) | MMP3MMP1MMP2CAPN1FCER2 | |
| SCHEMBL4425181 | 0.86 | MMP2 (0.74) | MMP3MMP1MMP2MMP9ADAM17 | |
| SCHEMBL4431930 | 0.86 | MMP1 (0.73) | MMP3MMP1MMP2MMP9ADAM17 | |
| SCHEMBL15505966 | 0.82 | MMP1 (1.00) | MMP3MMP1MMP2MMP9ADAM17 | |
| SCHEMBL6801588 | 0.82 | MMP2 (0.62) | MMP3MMP1MMP2MMP9ADAM17 | |
| SCHEMBL6798668 | 0.78 | ALDH1A1 (0.62) | — | |
| SCHEMBL20880302 | 0.77 | CAPN1 (0.72) | CAPN1 | |
| SCHEMBL10975356 | 0.77 | CAPN1 (0.73) | MMP3MMP1MMP2CAPN1 | |
| SCHEMBL4428170 | 0.76 | MMP2 (0.81) | MMP3MMP1MMP2MMP9ADAM17 | |
| SCHEMBL3837378 | 0.75 | CAPN1 (0.75) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | claimed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | claimed |
| CN-112469439-A | With leukotriene A4Hydrolase modulators for the treatment of aging-related diseases | 万能溶剂有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6306881-B1 | ENZYME INHIBITORS ADMINISTERED TO MAMMALS AS ANTIINFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2001-10-23 | — | — | US | disclosed |
| US-6251940-B1 | ADMINISTERING TO THE MAMMAL SUFFERING FROM A DISEASES RESPONSIVE TO INHIBIT MONOCYTE AND/OR MACROPHASE AND/OR LYMPHOCYTE ACTIVATION AND OF LYMPHOCYTE PROLIFERATION AN AMIDE DERIVATIVE | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2001-06-26 | — | — | US | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | MMP3 455/4885MMP1 644/4885MMP2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.